| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/03/2006 | WO2006079791A1 Chemical compounds |
| 08/03/2006 | WO2006079789A1 Pyrimidothiophene compounds having hsp90 inhibitory activity |
| 08/03/2006 | WO2006079720A1 Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents |
| 08/03/2006 | WO2006079719A2 Novel heterocyclic oxime derivatives, method for preparing same and pharmaceutical compositions containing same |
| 08/03/2006 | WO2006079675A1 Product for the treatment of atherogenic lipid disorders |
| 08/03/2006 | WO2006079656A1 Hiv inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives |
| 08/03/2006 | WO2006079653A1 N-hydroxyamide derivatives and use thereof |
| 08/03/2006 | WO2006079645A1 Novel indolopyridines , benzofuranopyridines and benzothienopyridines |
| 08/03/2006 | WO2006079644A1 Indolopyridines, benzofuranopyridines and benzothienopyridines |
| 08/03/2006 | WO2006079642A1 Anthelmintic imidazol-thiazole derivates |
| 08/03/2006 | WO2006079637A1 Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders |
| 08/03/2006 | WO2006079625A2 Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic |
| 08/03/2006 | WO2006079624A1 Metabolites of 2-arylpropionic acid derivatives and pharmaceutical compositions containing them |
| 08/03/2006 | WO2006079611A1 Crystalline forms of rosuvastatin calcium salt |
| 08/03/2006 | WO2006079568A2 Use of 3-sulfanylpropanamide derivatives for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof |
| 08/03/2006 | WO2006079563A1 Adapalene for the long-term treatment of acne vulgaris |
| 08/03/2006 | WO2006079559A2 The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
| 08/03/2006 | WO2006079556A2 Substituted 5-phenyl pyrimidines i in therapy |
| 08/03/2006 | WO2006079549A1 Salts of aripiprazole |
| 08/03/2006 | WO2006079548A1 Organic compounds |
| 08/03/2006 | WO2006079547A2 Spm 927 for add-on therapy of schizophrenia |
| 08/03/2006 | WO2006079539A2 Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity |
| 08/03/2006 | WO2006079535A1 Valnemulin salts with organic acids |
| 08/03/2006 | WO2006079478A1 2-phenylquinoxalines as inhibitors for mpp1 |
| 08/03/2006 | WO2006079476A1 Phantom phenomena treatment |
| 08/03/2006 | WO2006079474A1 Prevention and treatment of thromboembolic disorders |
| 08/03/2006 | WO2006079467A1 Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors |
| 08/03/2006 | WO2006079243A1 The use of flavonol and flavonol glycosides for stimulating growth of renal tubular epithelial cells to secrete the kidney secreting bone growth factor |
| 08/03/2006 | WO2006079217A1 Treatment of degenerative diseases with the x-linked inhibitor of apoptosis |
| 08/03/2006 | WO2006079216A1 Liposomal compositions for parenteral delivery of agents |
| 08/03/2006 | WO2006079212A1 Use of s-adenosylmethionme, vitamin e, and vitamin c for the treatment of oxidative liver injury or insulin resistance |
| 08/03/2006 | WO2006079209A1 Pulmonary compositions comprising a vitamin a compound and a surfactant and uses thereof |
| 08/03/2006 | WO2006066183A3 Novel saframycin analogs as therapeutic agents |
| 08/03/2006 | WO2006066011A3 Compounds and compositions as modulators of steroidal receptors and calcium channel activities |
| 08/03/2006 | WO2006065793A9 TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS |
| 08/03/2006 | WO2006065600A3 N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| 08/03/2006 | WO2006065480A3 Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| 08/03/2006 | WO2006065479A3 Substituted phenols as active agents inhibiting vegf production |
| 08/03/2006 | WO2006064375A9 Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases |
| 08/03/2006 | WO2006064355A3 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
| 08/03/2006 | WO2006064015A3 Diphenylurea derivatives useful as potassium channel activators |
| 08/03/2006 | WO2006063091A9 Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity |
| 08/03/2006 | WO2006062681A9 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 08/03/2006 | WO2006061638A3 Heterocycle derivatives as histone deacetylase (hdac) inhibitors |
| 08/03/2006 | WO2006061418A3 Methods and agents useful in treating conditions characterized by mucus hyperproduction/hypersecretion |
| 08/03/2006 | WO2006061417A3 Macrocyclic quinazole derivatives and their use as mtki |
| 08/03/2006 | WO2006061136A3 Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer’s disease |
| 08/03/2006 | WO2006060672A3 Modified release ciprofloxacin compositions |
| 08/03/2006 | WO2006060507A3 Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| 08/03/2006 | WO2006060145A3 Oral care composition comprising a phenolic compound and antioxidant vitamins and vitamin derivatives |
| 08/03/2006 | WO2006058893A3 Use of diacetyl trimer as an aromatic and flavouring substance |
| 08/03/2006 | WO2006058868A3 Substituted pteridines for treating inflammatory diseases |
| 08/03/2006 | WO2006057955A3 Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
| 08/03/2006 | WO2006057932A3 2-METHYLENE-18,19-DINOR-1α-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES |
| 08/03/2006 | WO2006055764A3 Use of methyl pyruvate to increase cellular energy production downstream of glycolysis |
| 08/03/2006 | WO2006055708A3 Heterocycle substituted carboxylic acids for the treatment of diabetes |
| 08/03/2006 | WO2006055503A3 Novel m3 muscarinic acetylcholine receptor antagonists |
| 08/03/2006 | WO2006055268A3 Pyrimidothienoindazoles capable of inhibiting tyrosine kinases of the epidermal growth factor |
| 08/03/2006 | WO2006053037A3 A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human |
| 08/03/2006 | WO2006052926A3 Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death |
| 08/03/2006 | WO2006052264A3 Synthesis, characterization and biological action of optically active isomers of floxacins |
| 08/03/2006 | WO2006051477A3 Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
| 08/03/2006 | WO2006050734A3 Potent lna oligonucleotides for the inhibition of hif-1a expression |
| 08/03/2006 | WO2006050509A3 Amorphous and polymorphic forms of telmisartan sodium |
| 08/03/2006 | WO2006050472A3 Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids |
| 08/03/2006 | WO2006050274A3 Methods and compositions for cytokine expression and treatment of tumors |
| 08/03/2006 | WO2006050109A3 Novel kinase inhibitors |
| 08/03/2006 | WO2006050007A3 Substituted indolizines and derivatives as cns agents |
| 08/03/2006 | WO2006048768A3 Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal |
| 08/03/2006 | WO2006047631A3 Anti-mitotic anti-proliferative compounds |
| 08/03/2006 | WO2006046934A3 Osteoclastogenesis inhibitors and uses thereof |
| 08/03/2006 | WO2006046100B1 Pharmaceutical composition of alendronic acid |
| 08/03/2006 | WO2006044762A3 Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor |
| 08/03/2006 | WO2006044502A3 Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| 08/03/2006 | WO2006042574A3 Sodium ascorbate solubilisate |
| 08/03/2006 | WO2006042021B1 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| 08/03/2006 | WO2006039697A3 Method of improving drugs with anti-retroviral and anti-cancer activity |
| 08/03/2006 | WO2006035277A3 Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
| 08/03/2006 | WO2006034391A3 Indole inhibitors of 15-lipoxygenase |
| 08/03/2006 | WO2006033734A3 Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
| 08/03/2006 | WO2006032432A3 Donepezyl salts |
| 08/03/2006 | WO2006032115A3 Composition against cardiovascular diseases |
| 08/03/2006 | WO2006027784A3 Bifunctional antibiotics for targeting rrna and resistance causing enzymes and for inhibition of anthrax lethal factor |
| 08/03/2006 | WO2006027346A3 Novel pyrazolopyrimidines |
| 08/03/2006 | WO2006023757A3 Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents |
| 08/03/2006 | WO2006020984A3 Cyclosporin formulations |
| 08/03/2006 | WO2006014262A3 Indoles having anti-diabetic activity |
| 08/03/2006 | WO2006008512A3 Anti-histaminic composition |
| 08/03/2006 | WO2006000339A3 Calcium trifluoroacetate for preparing antiangiogenetic medicaments |
| 08/03/2006 | WO2005123140A3 Preparation of macromolecular conjugates by four-component condensation reaction |
| 08/03/2006 | WO2005120483A3 Selective androgen receptor modulators and methods of use thereof |
| 08/03/2006 | WO2005118580A3 Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
| 08/03/2006 | WO2005115406A3 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents |
| 08/03/2006 | WO2005113007A3 Powders containing novel oligosaccharide mixtures and methods for producing the same |
| 08/03/2006 | WO2005112889A3 Transmucosal delivery formulations |
| 08/03/2006 | WO2005110470A3 Methods and compositions for the modulation of immune responses and autoimmune diseases by activating rp105 (cd180) |
| 08/03/2006 | WO2005107719A3 Pharmaceutical composition comprising hydrophobic drug having improved solubility |
| 08/03/2006 | WO2005104745A3 Muscarinic acetylcholine receptor antagonists |
| 08/03/2006 | WO2005102329A3 An innovative screening method for coronary heart disease and stroke |
| 08/03/2006 | WO2005099715A3 Treatment of ophthalmic conditions with mineralcorticoids |